Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Fortrea Clinical Research Unit Inc..
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
33actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-19 | actual | When the study began enrolling |
| Primary completion | 2025-10-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-02 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatic Impairment
Intervention
- Drug: AZD5004 — also filed as ECC5004, Dose 1
Primary outcomes
what the primary-completion date above is the date OFAUCinf
measured Day 1 to Day 6
AUClast
measured Day 1 to Day 6
Cmax
measured Day 1 to Day 6
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed